What is HC Wainwright’s Forecast for ACRV Q1 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.63) per share for the quarter. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($1.96) EPS.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Thursday, March 27th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.09.

ACRV has been the topic of several other reports. KeyCorp began coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Acrivon Therapeutics in a research report on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $23.17.

Acrivon Therapeutics Stock Performance

ACRV stock opened at $2.24 on Friday. The company has a market capitalization of $69.74 million, a PE ratio of -0.83 and a beta of 0.85. The company’s 50-day simple moving average is $5.35 and its 200 day simple moving average is $6.52. Acrivon Therapeutics has a 52 week low of $2.14 and a 52 week high of $11.90.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Barclays PLC grew its position in Acrivon Therapeutics by 51.2% in the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after purchasing an additional 11,273 shares in the last quarter. State Street Corp raised its stake in shares of Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after purchasing an additional 47,233 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after purchasing an additional 28,748 shares during the period. Exome Asset Management LLC purchased a new position in shares of Acrivon Therapeutics in the 3rd quarter worth about $817,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Acrivon Therapeutics during the fourth quarter valued at about $40,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.